Felicia Leccia1
Marie Batisse-Lignier1,2
Isabelle Sahut-Barnola1
Pierre Val1
A-Marie Lefrançois-Martinez1
Antoine Martinez1*
- 1UMR6293, GReD, INSERM U1103, CNRS, Clermont Université, Clermont-Ferrand, France
- 2Endocrinology, Diabetology and Metabolic Diseases Department, Centre Hospitalier Universitaire, School of Medicine, Clermont-Ferrand, France
Adrenal cortex tumors are divided into benign forms, such as primary hyperplasias and adrenocortical adenomas (ACAs), and malignant forms or adrenocortical carcinomas (ACCs). Primary hyperplasias are rare causes of adrenocorticotropin hormone-independent hypercortisolism. ACAs are the most common type of adrenal gland tumors and they are rarely “functional,” i.e., producing steroids. When functional, adenomas result in endocrine disorders, such as Cushing’s syndrome (hypercortisolism) or Conn’s syndrome (hyperaldosteronism). By contrast, ACCs are extremely rare but highly aggressive tumors that may also lead to hypersecreting syndromes. Genetic analyses of patients with sporadic or familial forms of adrenocortical tumors (ACTs) led to the identification of potentially causative genes, most of them being involved in protein kinase A (PKA), Wnt/β-catenin, and P53 signaling pathways. Development of mouse models is a crucial step to firmly establish the functional significance of candidate genes, to dissect mechanisms leading to tumors and endocrine disorders, and in fine to provide in vivo tools for therapeutic screens. In this article, we will provide an overview on the existing mouse models (xenografted and genetically engineered) of ACTs by focusing on the role of PKA and Wnt/β-catenin pathways in this context. We will discuss the advantages and limitations of models that have been developed heretofore and we will point out necessary improvements in the development of next generation mouse models of adrenal diseases.
Introduction
Adrenocortical tumors (ACTs) are classified as benign adrenocortical adenomas (ACAs) and malignant adrenocortical carcinomas (ACCs). Most ACTs are benign, unilateral, and non-secreting adenomas, often discovered incidentally during abdominal imaging for reasons unrelated with adrenal gland (adrenal “incidentalomas”). Although less frequently, ACAs may be secreting tumors associated with endocrine hyperfunction that leads to several symptoms and significant morbidity. Indeed, clinical manifestations of secreting ACAs differ depending on their secretion profile. Cortisol-producing adenomas (CPAs) lead to Cushing’s syndrome (CS). Notably, hypercortisolism associated with unilateral ACAs is the most common form of adrenocorticotropin hormone (ACTH)-independent CS (1, 2). Aldosterone-producing adenomas (APAs) lead to primary aldosteronism (PA). APAs, together with bilateral hyperplasia, comprise 95% of all PA cases (3).
Although bilateral forms of ACTs are less frequent, several adrenal pathological conditions converge in the group of diseases termed adrenocortical hyperplasia, characterized by bilateral adrenal enlargement. Primary bilateral macronodular adrenal hyperplasia (PBMAH) is the most common and is a rare cause of CS. The report of familial forms and the bilateral nature suggest a genetic origin for PBMAH (4). Unlike PBMAH, primary pigmented nodular adrenal hyperplasia (PPNAD) is rarer but it may cause overt Cushing (5).
Contrary to ACAs, ACCs are extremely rare, with an annual incidence of 0.5–2 cases per million. However, they are highly aggressive tumors associated with poor prognosis and often diagnosed at an advanced stage (6, 7). They can occur at any age but the incidence in children is particularly high in southern Brazil due to the high prevalence of a specific TP53 mutation (8). Besides tumor growth and metastasis, clinical manifestations of ACCs are often the result of steroid hypersecretion caused by endocrine dysfunction, reminiscent of adrenal adenomas.
Over the last 5 years, genetic analyses of patients with sporadic or familial forms of ACTs has resulted in identification of alterations in a new set of genes, most of them being involved in cAMP/protein kinase A (PKA) and Wnt/β-catenin signaling pathways (9–11) (Figures 1 and 2). The major difference in the prevalence of ACA and ACC in patients suggests that adenomas are not precursors of malignant neoplasms. Moreover, the malignant transformation of a benign and non-functional adrenal tumor is very rare (12–14). Notably, the risk that an adrenal incidentaloma progresses to a malignant tumor has recently been estimated as almost zero by the European Society of Endocrinology (ESE). Consequently, European recommendations for the clinical management of patients with non-functional ACAs have been reconsidered and modified to avoid unnecessary procedures (European Congress of Endocrinology, May 2016, Munich, Germany – Symposium 5: ESE clinical guidelines: Management of adrenal incidentaloma: http://www.ece2016.org/scientific-programme/). By contrast, secreting ACAs are surgically removed, which prevents evaluation of a possible benign to malignant continuum in functional adenomas. In fact, the hypothesis that ACC could develop in a multistep process from normal adrenal to adenoma followed by malignant transformation relied on one case report in which a carcinoma emerged in the center of a surrounding benign ACT (15). However, some genome-wide approaches performed on independent cohorts to analyze genomic changes and gene regulation in ACTs suggests that cancers could result from pangenomic cumulative changes occurring in a multistep tumor progression (16–18). Although it is important to predict to what extent a benign lesion can be considered as the precursor of malignancy, analysis of patients’ data may not be sufficient to provide a definitive conclusion.
Figure 1. PKA signaling pathway in adrenal tumorigenesis and related mouse models. (A) Under normal conditions, ACTH binds to MC2R, a G-protein-coupled receptor (GPCR) that activates adenylate cyclase (AC) via Gsα, thus increasing intracellular levels of cAMP. Upon binding of cAMP to regulatory subunits (R) of PKA, the complex dissociates releasing the catalytic subunits (C) which in turn phosphorylate (among others) the cAMP-responsive element-binding protein (CREB). Once phosphorylated, CREB transcription factor regulates the expression of steroidogenic and proliferative genes. In absence of ACTH, the pathway is repressed through the activity of several phosphodiesterases (PDE) that inactivate cAMP. (B) Molecular alterations of several components of cAMP/PKA signaling pathway cause adrenal hyperplasias and tumors. (1) Activating mutations of MC2R found in PBMAH patients lead to higher activation of the pathway. No mouse model is actually available for Mcr2 activating mutations. (2) Hormones other than ACTH (GIP/hCG/LH), through ectopic expression of several GPCRs, may induce ACTH-independent hypercortisolism in PBMAH patients. Xenograft mouse models nicely recapitulate this pathologic context. (3) Activating mutations in GNAS gene, encoding for the subunit α of the stimulatory G protein, causes higher activation of the pathway. These mutations are the cause of adrenal hyperplasia associated with Cushing’s syndrome in Mc-Cune Albright syndrome, whereas somatic mutations have been found in cortisol-producing adenomas. No mouse model is actually available for Gnas-activating mutations. (4) Inactivating mutations in PDE genes lead to an accumulation of cAMP, thus causing the persistent activation of the pathway in absence of ACTH and they have been associated with PBMAH and hypercortisolism. Whole-body PDE8B knockout mice developed mild hyperplasia. (5a) Most inactivating mutations in the PRKARIA gene, encoding the 1α regulatory subunit (R1α) of the PKA, lead to aberrant transcripts and to the absence of the protein, resulting in constitutive activation of PKA. Adrenocortical-specific Prkar1a knockout (AdKO) mice develop a PPNAD-like syndrome with adrenal hyperplasia and ACTH-independent hypercorticosteronism. (5b) Some PRKARIA gene mutations lead to expressed mutated (truncated) R1α proteins that also cause increased PKA activation. These mutations are associated with a more severe phenotype for reasons still not understood to date. No mouse model is available for expressed mutated R1α proteins. (6) Mutations in the PRKACA gene encoding for the catalytic subunit α (Cα) of the PKA alter its interaction with regulatory subunits leading to constitutive activation of PKA-Cα and increased steroidogenesis. These mutations have been identified in many patients with cortisol-producing adenomas. No mouse model is actually available for Prkaca activating mutations. (7) Inactivating germline and somatic mutations in the armadillo repeat-containing 5 (ARMC5) gene have been identified in ~50% of patients with PBMAH. The function and the mechanisms by which ARMC5 contributes to the pathogenesis of PBMAH are unknown. In vitro studies suggest a role in steroidogenesis and apoptosis processes and a possible interplay with the PKA pathway, which is supported by the association of ARMC5 mutations with particular expression profile of GPCRs. No loss of function mouse model is actually available for Armc5.
Figure 2. WNT/β-catenin signaling pathway in adrenal tumorigenesis. (A) In the absence of Wnt ligands, b-catenin is phosphorylated by a complex composed of GSK3b, CK1, APC, and AXIN. This phosphorylation targets b-catenin to proteosomal degradation, thus preventing its nuclear translocation. In this context, the T cell-specific factors (Tcf)/lymphoid enhancer-binding factor (Lef) represses target genes expression through association with transcriptional inhibitors. Secreted frizzled related proteins (SFRP) can inhibit extracellular Wnt signaling. (B) When WNT signaling is active, binding of Wnt ligands to their receptor complex (Frizzled/LRP5/6) induces the recruitment of Disheveled (Dsv) to the cytoplasmic domain of Frizzled and the phosphorylation of the cytoplasmic tail of LRP5/6 by CK1 and GSK3b. This induces delocalization of Axin to LRP5/6 and sequestration of the degradation complex. b-catenin degradation is, thus, reduced and it accumulates. Accumulated b-catenin enters the nucleus, binds to LEF/TCF transcription factors, and activates transcription of target genes. Mutations in several members of WNT/β-catenin signaling pathway have been identified in adrenal hyperplasias, adenomas, and carcinomas. Several mouse models have been developed to induce constitutive β-catenin activation either through adrenal cortex specific loss of Apc (1) or the expression of a protein resistant to phosphorylation and ubiquitin-dependent degradation (2). Loss of ZNRF3, a potential Wnt signaling inhibitor, has been identified as the major genetic alteration in adrenal carcinoma. Mouse model with adrenal specific inactivation of Znrf3 is required to assess its causal involvement in ACC.
The use of small animals for modeling tumors in a controlled experimental manner is a valuable strategy to explore the functional significance of mutations, to dissect mechanisms underlying both adrenocortical tumorigenesis and endocrine disorders, and to provide in vivo tools to screen for novel therapeutic approaches. To date, several genetically modified and xenografted mouse models have been developed to investigate the involvement of specific pathways and the heterogeneous nature of ACTs, respectively. Although models established until now have shed light on important aspects of adrenocortical diseases, many of them failed to fully mimic tumors found in human adrenals (Table 1). Hence, there is a strong need to develop relevant mouse models to shed light on mechanisms involved in the initiation and progression of adrenal tumors. In this article, we provide an overview of the existing mouse models (xenografted and genetically engineered) of ACTs relevant to human ACTs, including adrenal hyperplasia. We will discuss limitations of models that have been developed heretofore and we will point out necessary improvements in the development of next-generation mouse models of adrenal diseases. Notably, these models should allow, on the one hand, to firmly establish the role of newly identified genes in adrenocortical tumorigenesis and, on the other hand, to explore the interplay between pathways shown to be associated with ACTs (e.g., cAMP/PKA and Wnt/β-catenin).
Table 1. Current mouse models of adrenocortical tumors and their limitations.
Benign Adrenocortical Tumors and Associated Hypersecretion Syndromes
Primary Bilateral Macronodular Adrenal Hyperplasia
Primary bilateral macronodular adrenal hyperplasia is a rare cause of CS, accounting for <2% of all endogenous CS cases (33, 34). PBMAH is characterized by the presence of adrenocortical nodules larger than 10 mm and it is often diagnosed in patients between 40 and 60 years of age, with clinical signs of cortisol excess and suppressed levels of plasma ACTH. PBMAH was first described by Kirschner and colleagues (35) and it was named ACTH-independent macronodular adrenal hyperplasia (AIMAH). However, it has been recently found that cortisol production in PBMAH is not truly ACTH independent, since a population of adrenocortical cells in the hyperplastic tissue can produce ACTH that in turn stimulates cortisol secretion through autocrine and paracrine mechanisms (36). Hence, the term “ACTH independent” is not entirely appropriate for this disorder. Although in the majority of cases, PBMAH appears to be sporadic, several cases of familial clustering have been reported in the last years (37–39). However, the true prevalence of the familial vs. sporadic form is unknown, as systematic familial screening has not been conducted.
Aberrant Hormone Receptors in PBMAH and Related Mouse Models
The mechanism by which cortisol production is stimulated in PBMAH, despite suppressed plasma ACTH, was previously unknown and was referred to as being “autonomous.” Several groups have then shed light on the pathogenesis of hypercortisolism in PBMAH. They reported that in most patients with PBMAH and in some adenomas, cortisol secretion is regulated by hormones other than ACTH, through the aberrant expression of several G-protein-coupled receptors (GPCRs) that are normally absent (ectopic) or expressed at lower levels in the adrenal cortex (40–42). The GPCRs for gastric inhibitory polypeptide (GIP), catecholamines, vasopressin, serotonin, and luteinizing hormone/human chorionic gonadotropin (LH/hCG) have been shown to be involved in adrenal CS development (42). GIP-dependent CS has been reported in patients with PBMAH and with unilateral adenomas (33, 43, 44). In these patients, plasma cortisol levels were increased following meals, despite ACTH suppression, and paralleled postprandial elevation of GIP plasma concentrations. Hypercortisolism associated with aberrant LH/hCG receptors was first identified in a woman with transient CS during sequential pregnancies and persistent CS after menopause (45). Since then, several cases of PBMAH with aberrant LHR have been reported, alone or in association with GIPR (45, 46). The molecular mechanisms responsible for aberrant expression of these receptors are unknown as no genetic mutations have been found in the coding or regulatory regions of receptor genes. Furthermore, whether expression of these receptors is a primary or a secondary event in the pathogenesis of PBMAH is still a matter of debate. Several lines of evidence support the hypothesis that it is a causative factor. First, aberrant receptors are almost universally present in PBMAH and at early stages (47). Second, the same aberrant receptors were found in all members of some affected families (37, 48), although this was not found in a known Brazilian family (39). Further data supporting a triggering role of ectopic receptors in PBMAH came from xenotransplantation mouse models. Indeed, to investigate the role of ectopic GIPR and LHR expression in the development of PBMAH, Mazzuco and colleagues used an in vivo model of cell transplantation and tissue reconstruction. Primary bovine adrenocortical cells were genetically engineered to express GIPR or LHR (retrovirus-mediated enforced expression) and transplanted under the kidney capsule of adrenalectomized immunodeficient mice (49, 50). Transplantation of GIPR- or LHR-expressing cells induced the formation of hyperplasic and hypertrophic adrenocortical tissues. The growth advantage provided by aberrant receptors expression at least relied on increased proliferation rates of transplants but the downstream mechanisms supporting proliferation were not explored. These models nicely recapitulated the context of human PBMAH with GPCR-dependent CS. Indeed, LHR-dependent CS is not exclusively observed during pregnancies or after menopause (41). Likewise, in the LHR xenotransplanted model, the hyperplastic tissue formed in the absence of supraphysiological levels of plasma LH. This shows a direct role of aberrant LHR expression in the pathogenesis of PBMAH with LH-responsive CS, even though the molecular mechanisms leading to ectopic expression of GPCRs in adrenocortical cells are still unknown.
Xenotransplantation models developed by Mazzuco et al. are not easy to manage for long-term follow-up or for assessment of therapeutic strategies, because immunodeficient mice with CS have short life expectancy. However, this elegant approach combining genetic engineering and cell transplantation of bovine adrenal cells in mice may be a useful tool to test the cooperation of multiple genetic alterations in the tumorigenic process (51) or when genetic alterations may be not relevant in mouse (e.g., KCNJ5 gene, see Aldosterone-Producing Adenomas: WNT Pathway, KCNJ5, and Lack of Mouse Models).
Familial Forms of PBMAH, Genetic Alterations, and Related Mouse Models
Reports of rare familial forms and the bilateral nature of these tumors support a genetic origin of PBMAH. Many genes are associated with the development of PBMAH, including genes causing hereditary familial tumor syndromes, such as APC (52, 53), MEN1 (54), and FH (55). Moreover, several reports pointed out genes involved in the cAMP/PKA signaling pathway, such as PDE8B and PDE11A (56, 57), MC2R (58), GNAS (59), and PRKACA (9) (Figure 1). Mutations in members of cAMP/PKA pathway are predicted to over-activate the pathway but they have been observed in a limited number of patients (Figure 1).
Germline inactivating mutations of the MEN1 gene cause a complex genetic syndrome named multiple endocrine neoplasia type 1 (MEN1) characterized by endocrine and non-endocrine tumors (60). PBMAH occurs in ~21% of MEN1 patients (54). Two whole-body Men1 KO mouse models have been reported. They nicely recapitulate the spectrum of tumors of MEN1 syndrome, including adrenocortical lesions. Specifically, whereas homozygous whole-body Men1 KO is embryonic lethal (19, 20), heterozygous mice are viable and develop tumors similar to those found in the human disease, including adrenocortical hyperplasia that seems to progress from adenoma to carcinoma (20). Of note, characterization of the histological phenotype, allowing establishment of tumor grade, was not detailed in this paper. Therefore, the conclusion that a multi-step tumor progression process occurs in Men1 adrenal tumors should be taken with caution (Table 1). Since MEN1 has recently been identified as a significantly mutated gene in ACC (11), Men1 KO mice could be useful to identify novel actors and mechanisms underlying the evolution of benign ACTs to malignancy.
Although the bilateral nature and the multifocal nodules suggest an important role of genetic factors in PBMAH, genetic defects summarized above account for only a few cases of this adrenal disease. More recently, inactivating germline and somatic mutations in the armadillo repeat-containing 5 (ARMC5) gene have been identified in ~50% of patients with apparently sporadic PBMAH and also in a large family with genetically transmitted PBMAH (10, 39, 61, 62). ARMC5 is a tumor suppressor gene with the typical “two-hit” pattern of mutations: a first germline mutation and a second somatic one. The function and the mechanisms by which ARMC5 contributes to the pathogenesis of PBMAH are unknown. However, in vitro studies suggest a role in steroidogenesis and apoptosis processes (10). Indeed, ARMC5 inactivation in cultured adrenocortical cells decreases the expression of MC2R and of various steroidogenic enzymes, both in basal conditions and after cAMP stimulation (10), suggesting that it may interfere with PKA pathway by impairing the stimulation of its target genes (Figure 1). Increased cell survival upon ARMC5 inactivation is proposed to trigger hyperplasia while subclinical CS could be the result of the major increase in adrenal mass that would compensate for decreased per-cell steroidogenic activity. Furthermore, ARMC5 mutations seem to be associated with particular expression profile of GPCRs, i.e., beta-adrenergic and dopamine receptors (10). This observation supports the hypothesis of a link between ARMC5 and PKA signaling, as the abnormal expression of GPCRs leads to activation of PKA signaling, normally triggered by the ACTH receptor (MC2R) (Figure 1). Further in vitro studies and the development of knockout models are required to shed light on the ARMC5-dependent network that triggers development of PBMAH and CS. Notably, the combination of adrenal targeted GPCRs overexpression and Armc5 knockout could provide information on a possible cooperation between ARMC5 and PKA signaling.
Primary Pigmented Nodular Adrenocortical Disease and Related Mouse Models
Primary pigmented nodular adrenocortical disease is a type of adrenal hyperplasia characterized by the presence of cortisol-secreting bilateral adrenal micronodules (<1 cm). PPNAD is the most common endocrine manifestation of Carney complex disease (CNC), an autosomal-dominant multiple neoplasia syndrome (63). More than 60% of CNC patients harbor mutations in the PRKARIA gene, encoding the regulatory subunit 1α (R1α) of PKA (64) (Figure 1). Specifically, inactivating heterozygous germline mutations are observed in about two-thirds of Carney Complex patients and loss of heterozygosity (LOH) has been reported, indicating that PRKARIA acts as a tumor suppressor gene (64). Interestingly, somatic inactivating mutations have also been found in ACTs (65). Several mouse models have been developed to target Prkar1a gene inactivation by different strategies (Table 1). Total Prkar1a KO mice had severe defects in mesoderm development and died at E9.5 (66). Mice heterozygous for a null allele of Prkar1a developed several tumors but had no adrenal phenotype (21). An antisense RNA approach was developed to achieve a more severe loss of R1α than in heterozygous KO mice (22). This allowed a 70% decrease in Prkar1a, causing several neoplastic manifestations, including mild adrenocortical hyperplasia. Interestingly, adrenocortical manifestations in the antisense RNA model included maintenance of the X-zone, a normally transient zone of fetal origin. To achieve bi-allelic inactivation without compromising mouse survival, we generated an adrenocortical-specific Prkar1a knockout mouse model (AdKO) (23) by crossing Prkar1a-floxed strain with Akr1b7-Cre mice, thereby targeting specific genetic ablation in adrenocortical cells from E14.5 (67) (Figures 1 and 3; Table 1). These mice developed a PPNAD-like syndrome with ACTH-independent hyper-corticosteronism and adrenal hyperplasia, composed of hypertrophic cells emerging from the innermost cortex. Endocrine overactivity was associated with unbuffered PKA catalytic activity, which resulted in overexpression of steroidogenic genes. Interestingly, fetal-like hyperplasia centrifugally expanded with aging at the expense of the normal adult cortex, which underwent progressive atrophy. This mouse model confirmed the important role of PKA pathway in adrenal hyperplasia and shed light on possible mechanisms responsible for PPNAD. The most likely mechanism to explain the defective zonal differentiation and cell renewal in AdKO mice is an impaired capacity of adult progenitor cells of the outer cortex to undergo centripetal differentiation and increased survival of cells in the inner cortex that would then cumulate both fetal-like and fasciculata cell features. We further showed that PKA-dependent induction of mTOR signaling was one of the mechanisms participating in the resistance to apoptosis, leading to both hyperplasia and cell hypertrophy, typical of PPNAD (68, 69). Altogether, these observations suggest that PPNAD should be considered as a developmental disease.
To further elucidate the molecular mechanisms by which PKA pathway contributes to the initiation and/or development of adrenal disorders, it is essential to provide deeper insight of its interplay with other signaling pathways (Figure 3). Interestingly, WNT pathway activation has been involved in both PBMAH and PPNAD (70, 71) (Figure 2). Furthermore, as we will discuss in next sections, WNT pathway is also associated with ACA and ACC. A possible interplay between WNT/β-catenin and cAMP/PKA pathways in the pathogenesis of adrenal hyperplasia and tumors would be an important point to further investigate with mouse models (Figure 3).
Figure 3. Interplay between the WNT/β-catenin and the cAMP/PKA pathways in the pathogenesis of adrenal hyperplasias and tumors. (A) Two mouse models recapitulating some of the most frequent alterations found in adrenal tumors in patients. AdKO mice developed cortical hyperplasia as a result of constitutive PKA activation due to gene inactivation of R1a regulatory subunit of PKA. The increased PKA signaling also favored zona fasciculata cell identity and glucocorticoid excess. ΔCat mice developed cortical adenoma as a result of constitutive b-catenin due to deletion of exon 3 in the gene encoding the b-catenin (Ctnnb1) leading to protein stabilization. Increased b-catenin activation also induced ectopic differentiation of zona glomerulosa and aldosterone excess. (B) Our models demonstrated that Prkar1a is a tumor suppressor and Ctnnb1 is an adrenal oncogene but secondary genetic alterations are required for malignant progression. A possible interplay between the WNT/β-catenin and the cAMP/PKA pathways in the adrenal cortex zonation and tumorigenesis is an important point to further investigate. The question can be genetically addressed by using compound transgenic mice based on previous available models and carrying both β-catenin and PKA constitutive activation.
Cortisol-Producing Adenomas: PKA Pathway, PRKACA Mutations, and Lack of Mouse Models
As discussed above (Sections “Familial Forms of PBMAH, Genetic Alterations, and Related Mouse Models” and “Primary Pigmented Nodular Adrenocortical Disease and Related Mouse Models”), a number of genetic defects in the cAMP/PKA pathway have been associated with adrenal hyperplasia and related to cortisol hypersecretion (Figure 1). Somatic mutations of GNAS (72–74) and PRKAR1A (75) have also been found in CPAs (Figure 1). However, these mutations only accounted for a small subset of CPAs, which represent a relevant cause of CS. Recently, Beuschlein and collaborators identified a hotpsot mutation (L205R) in the PRKACA gene, encoding the catalytic subunit α (Cα) of PKA, in more than one-third of patients with CPA (9). Four other groups subsequently reported the same mutation (72–74, 76). The PRKACA L205R mutation results in constitutive PKA activation (9, 74), which is a very likely cause of ACT formation (Figure 1). Supporting this hypothesis, patients with somatic mutations had adenomas, whereas patients with germline duplications had bilateral hyperplasias. Hence, PRKACA mutations, together with the previously identified GNAS and PRKAR1A inactivating mutations, strongly support a crucial role of cAMP/PKA pathway in the tumorigenesis of CPAs. The development of knock-in mouse models bearing PRKACA activating L205R mutation is required to evaluate its driver potential and to provide new insights into the mechanisms underlying PKA-dependent tumorigenesis in the context of cortisol-producing ACAs. In addition, adding extra copies of Prkaca in mouse, by additive transgenesis or targeted transgenesis at the Rosa26 locus, would provide an opportunity to explore the pathogenic, maybe oncogenic, potential of PKA signaling. Such complementary mouse models would help understanding if gain-of-function mutations and gain of copy number alterations result in distinct adrenal lesions. Activating mutations in CTNNB1, the gene encoding β-catenin, have also been identified in CPAs (77). Interestingly, the recently identified PRKACA mutations were shown to be mutually exclusive with CTNNB1 mutations (72–74, 76). Therefore, a possible interplay between WNT/β-catenin and cAMP/PKA pathways in CPAs remains to be investigated. Once again, mouse models should be invaluable tools to address this question in vivo (Figure 3).
Aldosterone-Producing Adenomas: WNT Pathway, KCNJ5, and Lack of Mouse Models
In recent years, high throughput next-generation sequencing technologies have allowed major advances in the knowledge of the genetic bases of APAs. By comparing the APA exome to the germline exome, recurrent somatic mutations have been identified in genes coding for ion channels and transporters regulating the cell membrane potential. Specifically, mutated genes encoding ion channels include KCNJ5, which encodes the G-protein activated potassium channel GIRK4, and is mutated in about 26–40% of APAs (78, 79) and CACNA1D and CACNA1H genes encoding for voltage-dependent calcium channels (80, 81). Genes encoding regulators of the cell membrane potential include two ATPases, ATP1A1 and ATP2B3 (82). All these mutations ultimately lead to increased intracellular calcium and abnormal activation of calcium–calmodulin-dependent kinase (Ca2+–CAMK) signaling, which plays a central role in aldosterone production. Before identification of these novel APA-associated genes, several mouse models of potassium channels inactivation (KCNK3/KCNK9 inactivation models) allowed understanding the effects of calcium homeostasis disruption and of some important aspects of PA (83–85). However, none of these models recapitulated hyperplasia and/or tumor development observed in human disease. Although one cannot exclude that mouse adrenal context may not be relevant to reproduce pathophysiological conditions associated with APA formation in humans, this suggests that in APAs, the tumorigenic potential could rely on a yet unidentified alteration. Among the newly identified genes, KCNJ5 mutations represent the most frequent genetic defects in APAs, with higher prevalence in the Japanese population (79). Thus, animal models of KCNJ5 inactivation are warranted to confirm a central role for this gene in the initiation of APAs. However, Kcnj5 mRNA and KCNJ5 protein are not expressed in the rat adrenal cortex, suggesting that it does not play a role in adrenal steroid production in this species and very likely in mice (86). Therefore, the demonstration that loss of KCNJ5 is sufficient to initiate both hyperaldosteronism and tumor development will require genetic approaches in non-mouse systems, such as primary bovine adrenocortical cells and tissue reconstruction in xenografted mice.
Both cAMP/PKA and WNT/β-catenin pathways have been involved in the development of CPAs. Similarly, WNT/β-catenin pathway plays an important role in APA development, in addition to calcium signaling. Indeed, by generating a mouse model with constitutive β-catenin activation in the adrenal gland (ΔCat model), we found that these mice developed progressive dysplasia and hyperplasia, ectopic differentiation of zona glomerulosa (ZG), and increased aldosterone production (Table 1). The ΔCat model will be further discussed in the ACC section. In a subsequent paper, Berthon and colleagues reported that WNT/β-catenin pathway was aberrantly activated in 70% of a series of 47 patients, which was the most frequent alteration reported in APAs (87). Furthermore, a recent study has reported CTNNB1 mutations in 5.1% of a cohort of 198 APAs (88). These mutations were associated with stabilized β-catenin, suggesting activation of WNT pathway (Figure 2). Because of the higher frequency of WNT/β-catenin activation than of CTNNB1 mutations, it is essential to expand our knowledge of the other causes of aberrant WNT/β-catenin activation, by investigating other members of the pathway or possible crosstalks with other pathways. Interestingly, decreased expression of the WNT inhibitor SRFP2 was shown to contribute to deregulation of WNT/β-catenin pathway in the adrenal (87) (Figure 2).
Adrenocortical Carcinomas: The Lack of Mouse Models
Adrenocortical carcinomas are extremely rare, with an annual incidence of 0.5–2 cases per million in adults. However, they are highly aggressive tumors associated with poor prognosis and often diagnosed at an advanced stage for which available treatments are rarely curative. The overall 5-year survival rates range from 10 to 40% (6, 7). ACCs can occur at any age, but the incidence in children is particularly high in southern Brazil due to the high prevalence of a specific germline mutation (p.R337H) of the TP53 tumor suppressor gene (8). Pediatric and adult ACCs differ in genetics and many other ways (89, 90), as will be further discussed in Section “Pediatric ACCs: TP53, SF1, and Related Mouse Models.” Although most ACCs arise sporadically, an increased incidence of ACCs has been reported in some genetic syndromes, such as familial adenomatous polyposis (FAP), characterized by mutations in APC and elevated Wnt/β-catenin signaling, and Beckwith–Wiedemann syndrome (BWS), characterized by elevated expression of insulin-like growth factor-2 (IGF2) (91, 92).
The developmental context of the disease is crucial for the treatment and management of adrenal tumors. Therefore, there is a strong need to generate mouse models resembling human pathology, to identify the mechanisms involved in benign to malignant progression. Up to now, the three most frequent alterations that have been reported in ACC patients include overexpression of IGF2 (93, 94), activation of WNT/β-catenin signaling pathway (11, 77, 95), and inactivation of TP53/RB pathway (96, 97). Several mouse models of deregulation of these pathways have been generated, which allowed better understanding of adrenal tumorigenesis. However, none of these models was able to recapitulate full-fledged ACC development (Table 1). In the following sections, we summarize mouse models of ACC generated up to now, and focus on what is still lacking for a better understanding of adrenal tumor initiation and progression.
Mouse Models of WNT/β-Catenin and IGF2 Signaling Activation Are Insufficient to Trigger ACC Formation
The WNT/β-catenin pathway is essential for embryonic development and cell renewal in adult adrenal cortex where β-catenin is expressed and active in ZG (98) (Figure 3). Several tumor profiling studies have reported mutations in β-catenin gene (CTNNB1) in both ACAs and ACCs (77, 99, 100), suggesting that β-catenin activating mutations could be involved in adrenal tumor initiation and progression to malignancy. To assess this hypothesis, we have generated a mouse model of constitutive β-catenin activation in the adrenal cortex (ΔCat mice) (25) (Figures 2 and 3; Table 1). ΔCat mice were generated by mating mice harboring a floxed allele of β-catenin [Catnblox(ex3)] (101) with mice expressing the Cre recombinase in steroidogenic cells of the adrenal cortex, through the Akr1b7 promoter region (67). Cre-mediated excision of the third exon of Ctnnb1 gene prevents β-catenin phosphorylation and ubiquitin-dependent degradation, which induces accumulation of the protein and constitutive activation of its target genes. ΔCat mice showed adrenal hyperplasia and ectopic differentiation of ZG. However, aggressive tumor formation was only observed in a subset of 17-month-old animals. Our model demonstrated that Ctnnb1 was an adrenal oncogene but it also suggested that secondary genetic alterations were required for malignant progression. Through a different approach, Hammer and colleagues obtained similar results by generating mice with adrenal cortex specific loss of Apc (APC KO mice) (26), a component of the multi-protein destruction complex of β-catenin, to target WNT pathway activation (Figure 2). As ΔCat mice, APC KO mice displayed hyperplasia. Furthermore, hyperplasia progressed to microscopic and macroscopic adenomas as early as 15 weeks of age, but progression to carcinoma was never observed (Table 1). Results from our two groups suggest that constitutive activation of β-catenin initiates benign tumor development but is not sufficient to trigger malignant evolution.
Insulin-like growth factor-2 is a growth factor involved in the control of cell proliferation and inhibition of apoptosis and it was hypothesized to interact with the Wnt/β-catenin pathway. In sporadic adrenal tumors, IGF2 is overexpressed in 80–90% of ACCs but not in ACAs (93, 94). Several transgenic mouse models have been generated to explore the role of IGF2 in adrenal tumorigenesis (Table 1). Mice with overexpression of IGF2 under the control of phosphoenolpyruvate carboxykinase (PEPCK) promoter showed four- to sixfold elevation of serum IGF2 levels and mild adrenocortical hyperplasia but did not develop ACTs (27), suggesting that IGF2 overexpression was not involved in initiation of adrenal tumorigenesis. We have generated transgenic mice with adrenal cortex specific overexpression of IGF2 (AdIgf2 mice) (28) (Table 1). These mice had up to sevenfold higher basal levels of IGF2 (up to 87-fold higher with ACTH stimulation), but again they did not show tumor formation despite a mild increase in cortical cell proliferation. These results indicated that IGF2 alone could stimulate adrenal cortex proliferation but it was not able to induce oncogenic transformation. The mitogenic effect of IGF2 overexpression suggests a role in tumor maintenance rather than initiation, which would rather be triggered by other actors, such as WNT pathway. This two-step model is supported by the fact that IGF2 overexpression is found only in ACCs, whereas mutations in β-catenin are reported in both ACAs and ACCs. To test the hypothesis of cooperation between IGF2 and WNT pathways, we generated a mouse model presenting both genetic alterations, by mating ΔCat mice with IGF2 overexpressing mice (28) (Table 1). Our analysis of this model clearly showed that IGF2 overexpression in the context of constitutive WNT/β-catenin pathway activation only had a moderate effect on tumor progression. In another approach, Hammer and collaborators generated a mouse model with both loss of APC, to achieve WNT activation, and loss of imprinting at the Igf2/H19 region, to achieve elevated IGF2 expression (26) (Table 1). These mice displayed adrenocortical hyperplasia, microscopic and macroscopic adenomas, and cancer formation. Although the phenotype was more severe than that observed in mice presenting loss of APC alone, only one cancer formation was observed. Taken together, these results have clearly shown that genetic alterations in WNT pathway and IGF2 overexpression are not sufficient to trigger malignant adrenocortical tumorigenesis. Interestingly, we recently reported that expression of enhancer of zeste 2 (EZH2), a histone methyl transferase of the polycomb repressive complex 2 (PRC2), positively correlated with malignancy and poor prognosis in three different cohorts of patients with ACTs (102). In this study, we provided evidence that in the H295R human adrenal cancer cell line, EZH2 downregulation or pharmacological inhibition significantly decreased cell proliferation and aggressive behavior and induced apoptosis. Interestingly, EZH2 overexpression was shown to be the result of P53/RB/E2F pathway deregulation in good agreement with ACC omic studies. Although this remains to be demonstrated in a relevant animal model, these data suggest that EZH2 could be involved in malignant progression. Mouse models with various ability to express Ezh2 (loss- and gain-of-function) are, thus, required to decipher the molecular mechanisms involved in EZH2-mediated malignant progression, i.e., transcription repression through PRC2 recruitment or activation (103) and to identify the actors that cooperate with WNT pathway in this process. Altogether, these mouse models indicate that malignant tumors may arise from typical adenomas even if this progression only affects a small proportion of benign tumors and requires additional alterations, such as EZH2 overexpression. One challenge of these studies is the evaluation of tumor staging in mouse models. Until now, mouse tumors have been evaluated with the same criteria as human tumors, i.e., essentially Weiss’s scoring. However, the transposability of these histologic criteria is unclear and the only undoubtful proof of malignant progression is metastatic dissemination, which was not observed in any of the models discussed above. Irrespective of this issue, inheritable tumors in mouse genetic models provide an invaluable tool to follow tumor initiation and progression. Whole genomic analyses in such models would provide a unique opportunity to demonstrate or invalidate the existence of a normal adrenal adenoma–carcinoma continuum in adrenocortical tumorigenesis.
Pediatric ACCs: TP53, SF1, and Related Mouse Models
In addition to overexpression of IGF2 and activation of WNT pathway, the third most frequent genetic alteration in ACCs is inactivation of TP53/RB pathway. Germline mutations in the p53 tumor suppressor gene are associated with the development of Li–Fraumeni syndrome (LFS), an autosomal-dominant cancer syndrome resulting in multiple malignancies, including ACCs (104, 105). The rate of germline TP53 mutations in ACCs is age-dependent, ranging from up to 80% in pediatric ACCs (97) to 3–7% in adults (96). A 10-fold increased incidence of ACCs is observed in Southern Brazil due to a germline mutation within the oligomerization domain of p53 (p.R337H). This germline mutation was first identified in 98% of children with ACCs (106). The p.R337H mutation was also present in 78% of children with sporadic ACTs in another series and in 13% of adult patients with ACCs (107). In adult ACTs, TP53 mutations are mostly somatic and were considered to represent a later step in tumorigenesis (108, 109). Several mouse models of p53 dysfunction have been generated, including targeted mutations, replicating proteins identified in humans with LFS (110, 111). These mice developed a large spectrum of tumors but not ACCs. Mouse models of adrenal-specific TP53 loss have not been generated to date, despite the high prevalence of TP53 mutations in ACCs. However, the adrenocortical dysplasia (Acd) mouse model (112), carrying an inactivating mutation in Tpp/Acd, which normally functions to protect telomerase, was used to explore the consequences of TP53 loss during adrenal tumorigenesis (Table 1). Interestingly, ablation of p53 (obtained by mating Acd mice with p53 null mice) rescued a number of characteristics of the Acd phenotype, including adrenal hypoplasia. This indicates that hypoplasia in Acd mice results from p53-mediated senescence. Moreover, the loss of p53 in Acd mice leads to development of ACC, suggesting that p53-mediated escape from senescence may contribute to adrenocortical carcinogenesis (29). Another approach to explore the consequences of p53 ablation during adrenal tumorigenesis consists in adrenal targeting of the Simian Virus 40 (SV40) large T antigen (TAg), a potent oncogene acting in part by inactivating p53 [reviewed in (113)]. TAg expressed under the control of several promoters has been used to induce ACTs in transgenic mice. In the inhibin-α (inha) promoter-TAg mouse, ACCs are induced by gonadectomy (30) (Table 1). This mouse model will not be discussed in details here as mouse models of gonadectomy-induced ACTs are beyond the scope of this review, being unrelated to the context of human adrenal tumors. In order to better recapitulate the context of human adrenal tumor development, we have generated a model in which TAg is expressed under the control of the adrenal cortex specific Akr1b7 promoter (31) (Table 1). In this AdTAg model 2 of 3 surviving founder mice developed adrenal tumors that were used to generate cell lines for further in vitro analysis (114). As exome sequencing and SNP array recently confirmed that p53/RB is one of the most frequently altered pathways in ACCs (11), future mouse models are needed to further explore the role of TP53 in adrenal tumor formation and progression. Considering the well-characterized antagonism of large TAg toward p53 and Rb tumor suppressors, one would predict that the AdTAg model could provide one of the most relevant and simple models to explore adrenal tumorigenic processes.
Transcriptional profiling has demonstrated distinct signatures of adult and pediatric ACCs with the pediatric tumor transcriptome displaying similarities to that of fetal adrenal tissue (115). Moreover, pediatric and adult ACCs differ in several clinical, pathological, and molecular aspects [reviewed in (90)], suggesting that they may represent genetically distinct entities. In addition to TP53, the genetic locus containing steroidogenic factor 1 gene (SF-1) is commonly amplified and overexpressed in pediatric ACCs (116, 117). SF-1 is a nuclear receptor transcription factor that plays an important role in the regulation of steroidogenic genes, in development and function of the adrenal cortex, and in male sexual differentiation (118, 119). In contrast to children, the frequency of amplification and overexpression in adult patients is very low (120), but it is associated with poor outcome (121). A transgenic mouse model, harboring multiple copies of a yeast artificial chromosome, including the SF-1 genetic locus, termed YACTR mice, has been generated (32) (Table 1). Although these mice developed adrenocortical hyperplasia that further progressed to adrenal tumors in a dose-dependent manner, the morphology of adrenal tumors differed from human ACTs and displayed a gonadal phenotype that was reminiscent of ACTs occurring in gonadectomized mice. These tumors are thought to arise from pluripotent adreno-gonadal precursor cells lying beneath the outer adrenal connective capsule, which have the potential to differentiate into cells of gonadal phenotype (122). Similarly, in YACTR mice, high levels of SF-1 may trigger proliferation of pluripotent cells and the development of adrenal tumors with a gonadal phenotype. Despite the differences in tumor phenotypes in human and mice, SF-1 appears to play an important role in adrenal tumorigenesis in both species. Recently, it has been proposed that SF-1 overexpression induces alterations of redox mechanisms, which may contribute to adrenal tumorigenesis. Indeed, inactivation of SF1 target gene Vnn1, encoding the Vanin-1 protein involved in the response to oxidative stress, was found to antagonize the development of adrenocortical neoplasia in SF-1 transgenic mice (123).
Novel Identified Genes in ACCs: Interplays with WNT Pathway and Need for In Vivo Studies
Recent OMIC studies confirmed that the most frequent genetic alterations in ACCs affect the tumor suppressor gene TP53 and the oncogene CTNNB1 (each being altered in ~16% of ACCs) (11, 124). In addition to pointing out alterations in already known drivers (CTNNB1 and TP53), these studies identified new genes not previously reported in ACCs. Among these new genes, ZNRF3 was found to be the most frequently altered (21% of ACCs). ZNRF3 encodes a protein with E3 ubiquitin ligase activity, supposed to act as a negative regulator of the WNT/β-catenin pathway (125) (Figure 2). ACCs with alterations in ZNRF3 locus showed activation of β-catenin target genes, but this activation was weaker than in tumors with CTNNB1 mutations (11). Interestingly, ZNRF3 and CTNNB1 alterations were mutually exclusive. Further functional studies and novel mouse models are needed to further explore the role of ZNRF3 in ACCs. Recurrent mutations have also been found in several known cell cycle regulators, including CDKN2A, CDK4, RB1, and CCNE1, confirming the notion that release from p53-sensitive checkpoints is a critical step in the process of adrenal tumorigenesis, a notion that previously emerged from analysis of p53 ablation in Acd mice.
Recently, mutations have also been found in PRKAR1A (126), a gene mutated in PPNAD (as discussed in Section “Primary Pigmented Nodular Adrenocortical Disease and Related Mouse Models”) and much more rarely in ACAs (as discussed in Section “Cortisol-Producing Adenomas: PKA Pathway, PRKACA Mutations, and Lack of Mouse Models”). These recent reports of PRKAR1A mutations expand the role of PKA signaling in ACC. If any functional interplay exists between the WNT/β-catenin and the cAMP/PKA pathways in the pathophysiology of adrenal cortex, this is an important point that remains to be clarified in vivo (Figure 3). As reviewed in Drelon’s study (127) data from the literature are in favor of such an interplay. This could influence normal adrenal cortex renewal/zonation as well as the pathophysiology of human adrenal tumors. However, whether these pathways cooperate or antagonize each other remains to be determined. This question could be genetically addressed by generating compound transgenic mice based on already available models carrying β-catenin and PKA constitutive activation (Figure 3) (23, 25).
Future Directions
The understanding of mechanisms of adrenal tumor progression is crucial for the management and treatment of the disease. Indeed, almost half of ACC patients present with metastatic disease and although mitotane alone or in combination with chemotherapy can improve patients’ survival, there is no efficient treatment for advanced disease. There is, thus, a strong need to generate mouse models resembling human pathology to identify actors involved in adrenal carcinogenesis. Especially, mouse models testing the role of newly identified genes in pediatric and adult ACCs are warranted. Moreover, as recent OMIC approaches confirmed that p53/RB is one of the most frequently altered pathways in ACCs (11), the AdTAg mouse model, previously used to generate cell lines for in vitro analyses (114), now becomes a relevant model for the study of ACCs.
The study of molecular mechanisms underlying malignant tumor progression represents a crucial step to develop novel specific drugs. The next step is to test their efficacy through in vitro and in vivo experiments. The only available “in vivo” model is the ACC xenograft obtained by subcutaneous injection of the H295R cell line in nude mice (128). Although this model has been extensively used to evaluate new and established drugs, it is important to take its limitations into account. These include deregulated antitumoral response resulting from immunodeficiency and abnormal or deficient microenvironment associated with subcutaneous injection of cells. Therefore, the AdTAg mouse model could be a useful experimental platform to assess in vivo the role of newly identified candidates potentially involved in malignant progression, such as EZH2 (102), using genetic or pharmacological approaches. Considering pediatric adrenal cancers, knock-in mouse models reproducing TP53 p.R337H mutation found in Brazilian families will be a major advance in our understanding of the pathogenesis of these destructive tumors. There is, thus, a strong need for novel mouse models for preclinical studies.
Finally, high throughput next-generation sequencing technologies have allowed major advances in the knowledge of the genetic bases of ACAs. Among the newly identified genes, ARMC5, KCNJ5, and PRKACA mutations represent the most frequent genetic defects in PBMAH, APAs, and CPAs, respectively (10, 39, 61, 62, 72–74, 79). Mouse models are required to confirm the driving potential of these genes in the initiation and/or progression of ACAs. In conclusion, we expect that the progress in gene editing methods and the recent identification of new recurrently mutated genes, will soon allow the development of novel mouse models capable of faithfully reproducing human adrenal diseases, overcoming the limitations of current models. These models will be useful, on the one hand, to investigate the mechanisms underlying malignant progression of adrenal tumors and, on the other hand, to develop novel therapeutic approaches.
Author Contributions
FL and AM wrote the manuscript. All authors edited the manuscript.
Conflict of Interest Statement
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Funding
We acknowledge the Université Blaise Pascal, Université d’Auvergne, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale, Agence National de la Recherche (grant ANR-14-CE12-0007), Fondation ARC pour la Recherche sur le Cancer (PJA 20141201894), and La Fondation de France, which supported our lab activity.
Abbreviations
ACA, adrenocortical adenoma; ACC, adrenocortical carcinoma; ACT, adrenocortical tumor; ACTH, adrenocorticotropin hormone; APA, aldosterone-producing adenoma; CPA, cortisol-producing adenoma; CS, Cushing’s syndrome; GIP, gastric inhibitor polypeptide; GPCR, G-protein-coupled receptors; LH/hCG, luteinizing hormone/choriogonaotropin; PA, primary aldosteronism; PBMAH, primary bilateral macronodular adrenal hyperplasia; PKA, protein kinase A; PPNAD, primary pigmented nodular adrenal hyperplasia; SF-1, steroidogenic factor 1.
References
1. Stratakis CA. Cushing syndrome caused by adrenocortical tumors and hyperplasias (corticotropin-independent Cushing syndrome). Endocr Dev (2008) 13:117–32. doi:10.1159/000134829
2. Calebiro D, Di Dalmazi G, Bathon K, Ronchi CL, Beuschlein F. cAMP signaling in cortisol-producing adrenal adenoma. Eur J Endocrinol (2015) 173:M99–106. doi:10.1530/EJE-15-0353
3. Fagugli RM, Taglioni C. Changes in the perceived epidemiology of primary hyperaldosteronism. Int J Hypertens (2011) 2011:162804. doi:10.4061/2011/162804
4. Hsiao H-P, Kirschner LS, Bourdeau I, Keil MF, Boikos SA, Verma S, et al. Clinical and genetic heterogeneity, overlap with other tumor syndromes, and atypical glucocorticoid hormone secretion in adrenocorticotropin-independent macronodular adrenal hyperplasia compared with other adrenocortical tumors. J Clin Endocrinol Metab (2009) 94:2930–7. doi:10.1210/jc.2009-0516
5. Bertherat J, Horvath A, Groussin L, Grabar S, Boikos S, Cazabat L, et al. Mutations in regulatory subunit type 1A of cyclic adenosine 5’-monophosphate-dependent protein kinase (PRKAR1A): phenotype analysis in 353 patients and 80 different genotypes. J Clin Endocrinol Metab (2009) 94:2085–91. doi:10.1210/jc.2008-2333
6. Wajchenberg BL, Albergaria Pereira MA, Medonca BB, Latronico AC, Campos Carneiro P, Alves VA, et al. Adrenocortical carcinoma: clinical and laboratory observations. Cancer (2000) 88:711–36. doi:10.1002/(SICI)1097-0142(20000215)88:4<711::AID-CNCR1>3.0.CO;2-W
7. Else T, Kim AC, Sabolch A, Raymond VM, Kandathil A, Caoili EM, et al. Adrenocortical carcinoma. Endocr Rev (2014) 35:282–326. doi:10.1210/er.2013-1029
8. Custódio G, Komechen H, Figueiredo FRO, Fachin ND, Pianovski MAD, Figueiredo BC. Molecular epidemiology of adrenocortical tumors in southern Brazil. Mol Cell Endocrinol (2012) 351:44–51. doi:10.1016/j.mce.2011.10.019
9. Beuschlein F, Fassnacht M, Assié G, Calebiro D, Stratakis CA, Osswald A, et al. Constitutive activation of PKA catalytic subunit in adrenal Cushing’s syndrome. N Engl J Med (2014) 370:1019–28. doi:10.1056/NEJMoa1310359
10. Assié G, Libé R, Espiard S, Rizk-Rabin M, Guimier A, Luscap W, et al. ARMC5 mutations in macronodular adrenal hyperplasia with Cushing’s syndrome. N Engl J Med (2013) 369:2105–14. doi:10.1056/NEJMoa1304603
11. Assié G, Letouzé E, Fassnacht M, Jouinot A, Luscap W, Barreau O, et al. Integrated genomic characterization of adrenocortical carcinoma. Nat Genet (2014) 46:607–12. doi:10.1038/ng.2953
12. Barzon L, Sonino N, Fallo F, Palu G, Boscaro M. Prevalence and natural history of adrenal incidentalomas. Eur J Endocrinol (2003) 149:273–85. doi:10.1530/eje.0.1490273
13. Cawood TJ, Hunt PJ, O’Shea D, Cole D, Soule S. Recommended evaluation of adrenal incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is similar to the risk of the adrenal lesion becoming malignant; time for a rethink? Eur J Endocrinol (2009) 161:513–27. doi:10.1530/EJE-09-0234
14. Kastelan D, Kraljevic I, Dusek T, Knezevic N, Solak M, Gardijan B, et al. The clinical course of patients with adrenal incidentaloma: is it time to reconsider the current recommendations? Eur J Endocrinol (2015) 173:275–82. doi:10.1530/EJE-15-0199
15. Bernard M-H, Sidhu S, Berger N, Peix J-L, Marsh DJ, Robinson BG, et al. A case report in favor of a multistep adrenocortical tumorigenesis. J Clin Endocrinol Metab (2003) 88:998–1001. doi:10.1210/jc.2002-021117
16. Ronchi CL, Sbiera S, Leich E, Henzel K, Rosenwald A, Allolio B, et al. Single nucleotide polymorphism array profiling of adrenocortical tumors – evidence for an adenoma carcinoma sequence? PLoS One (2013) 8:e73959. doi:10.1371/journal.pone.0073959
17. Gara SK, Wang Y, Patel D, Liu-Chittenden Y, Jain M, Boufraqech M, et al. Integrated genome-wide analysis of genomic changes and gene regulation in human adrenocortical tissue samples. Nucleic Acids Res (2015) 43:9327–39. doi:10.1093/nar/gkv908
18. Barreau O, de Reynies A, Wilmot-Roussel H, Guillaud-Bataille M, Auzan C, Rene-Corail F, et al. Clinical and pathophysiological implications of chromosomal alterations in adrenocortical tumors: an integrated genomic approach. J Clin Endocrinol Metab (2012) 97:E301–11. doi:10.1210/jc.2011-1588
19. Bertolino P, Radovanovic I, Casse H, Aguzzi A, Wang Z-Q, Zhang C-X. Genetic ablation of the tumor suppressor menin causes lethality at mid-gestation with defects in multiple organs. Mech Dev (2003) 120:549–60. doi:10.1016/S0925-4773(03)00039-X
20. Crabtree JS, Scacheri PC, Ward JM, Garrett-Beal L, Emmert-Buck MR, Edgemon KA, et al. A mouse model of multiple endocrine neoplasia, type 1, develops multiple endocrine tumors. Proc Natl Acad Sci U S A (2001) 98:1118–23. doi:10.1073/pnas.98.3.1118
21. Kirschner LS, Kusewitt DF, Matyakhina L, Towns WH, Carney JA, Westphal H, et al. A mouse model for the Carney complex tumor syndrome develops neoplasia in cyclic AMP-responsive tissues. Cancer Res (2005) 65:4506–14. doi:10.1158/0008-5472.CAN-05-0580
22. Griffin KJ, Kirschner LS, Matyakhina L, Stergiopoulos SG, Robinson-White A, Lenherr SM, et al. A transgenic mouse bearing an antisense construct of regulatory subunit type 1A of protein kinase A develops endocrine and other tumours: comparison with Carney complex and other PRKAR1A induced lesions. J Med Genet (2004) 41:923–31. doi:10.1136/jmg.2004.028043
23. Sahut-Barnola I, de Joussineau C, Val P, Lambert-Langlais S, Damon C, Lefrançois-Martinez A-M, et al. Cushing’s syndrome and fetal features resurgence in adrenal cortex-specific Prkar1a knockout mice. PLoS Genet (2010) 6:e1000980. doi:10.1371/journal.pgen.1000980
24. Tsai L-CL, Shimizu-Albergine M, Beavo JA. The high-affinity cAMP-specific phosphodiesterase 8B controls steroidogenesis in the mouse adrenal gland. Mol Pharmacol (2011) 79:639–48. doi:10.1124/mol.110.069104
25. Berthon A, Sahut-Barnola I, Lambert-Langlais S, de Joussineau C, Damon-Soubeyrand C, Louiset E, et al. Constitutive beta-catenin activation induces adrenal hyperplasia and promotes adrenal cancer development. Hum Mol Genet (2010) 19:1561–76. doi:10.1093/hmg/ddq029
26. Heaton JH, Wood MA, Kim AC, Lima LO, Barlaskar FM, Almeida MQ, et al. Progression to adrenocortical tumorigenesis in mice and humans through insulin-like growth factor 2 and β-catenin. Am J Pathol (2012) 181:1017–33. doi:10.1016/j.ajpath.2012.05.026
27. Weber MM, Fottner C, Schmidt P, Brodowski KM, Gittner K, Lahm H, et al. Postnatal overexpression of insulin-like growth factor II in transgenic mice is associated with adrenocortical hyperplasia and enhanced steroidogenesis. Endocrinology (1999) 140:1537–43. doi:10.1210/endo.140.4.6660
28. Drelon C, Berthon A, Ragazzon B, Tissier F, Bandiera R, Sahut-Barnola I, et al. Analysis of the role of Igf2 in adrenal tumour development in transgenic mouse models. PLoS One (2012) 7:e44171. doi:10.1371/journal.pone.0044171
29. Else T, Trovato A, Kim AC, Wu Y, Ferguson DO, Kuick RD, et al. Genetic p53 deficiency partially rescues the adrenocortical dysplasia phenotype at the expense of increased tumorigenesis. Cancer Cell (2009) 15:465–76. doi:10.1016/j.ccr.2009.04.011
30. Kananen K, Markkula M, Mikola M, Rainio EM, McNeilly A, Huhtaniemi I. Gonadectomy permits adrenocortical tumorigenesis in mice transgenic for the mouse inhibin alpha-subunit promoter/simian virus 40 T-antigen fusion gene: evidence for negative autoregulation of the inhibin alpha-subunit gene. Mol Endocrinol (1996) 10:1667–77. doi:10.1210/mend.10.12.8961275
31. Sahut-Barnola I, Lefrancois-Martinez AM, Jean C, Veyssiere G, Martinez A. Adrenal tumorigenesis targeted by the corticotropin-regulated promoter of the aldo-keto reductase AKR1B7 gene in transgenic mice. Endocr Res (2000) 26:885–98. doi:10.3109/07435800009048613
32. Doghman M, Karpova T, Rodrigues GA, Arhatte M, De Moura J, Cavalli LR, et al. Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol Endocrinol (2007) 21:2968–87. doi:10.1210/me.2007-0120
33. Lacroix A. ACTH-independent macronodular adrenal hyperplasia. Best Pract Res Clin Endocrinol Metab (2009) 23:245–59. doi:10.1016/j.beem.2008.10.011
34. Stratakis CA, Boikos SA. Genetics of adrenal tumors associated with Cushing’s syndrome: a new classification for bilateral adrenocortical hyperplasias. Nat Clin Pract Endocrinol Metab (2007) 3:748–57. doi:10.1038/ncpendmet0648
35. Kirschner MA, Powell RD, Lipsett MB. Cushing’s syndrome: nodular cortical hyperplasia of adrenal glands with clinical and pathological features suggesting adrenocortical tumor. J Clin Endocrinol Metab (1964) 24:947–55. doi:10.1210/jcem-24-10-947
36. Louiset E, Duparc C, Young J, Renouf S, Tetsi Nomigni M, Boutelet I, et al. Intraadrenal corticotropin in bilateral macronodular adrenal hyperplasia. N Engl J Med (2013) 369:2115–25. doi:10.1056/NEJMoa1215245
37. Vezzosi D, Cartier D, Régnier C, Otal P, Bennet A, Parmentier F, et al. Familial adrenocorticotropin-independent macronodular adrenal hyperplasia with aberrant serotonin and vasopressin adrenal receptors. Eur J Endocrinol (2007) 156:21–31. doi:10.1530/eje.1.02324
38. Watson TD, Patel SJ, Nardi PM. Case 121: familial adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing syndrome. Radiology (2007) 244:923–6. doi:10.1148/radiol.2443041507
39. Alencar GA, Lerario AM, Nishi MY, Mariani BM, Almeida MQ, Tremblay J, et al. ARMC5 mutations are a frequent cause of primary macronodular adrenal Hyperplasia. J Clin Endocrinol Metab (2014) 99:E1501–9. doi:10.1210/jc.2013-4237
40. Lacroix A, Ndiaye N, Tremblay J, Hamet P. Ectopic and abnormal hormone receptors in adrenal Cushing’s syndrome. Endocr Rev (2001) 22:75–110. doi:10.1210/edrv.22.1.0420
41. Bourdeau I, D’Amour P, Hamet P, Boutin JM, Lacroix A. Aberrant membrane hormone receptors in incidentally discovered bilateral macronodular adrenal hyperplasia with subclinical Cushing’s syndrome. J Clin Endocrinol Metab (2001) 86:5534–40. doi:10.1210/jcem.86.11.8062
42. Lacroix A, Baldacchino V, Bourdeau I, Hamet P, Tremblay J. Cushing’s syndrome variants secondary to aberrant hormone receptors. Trends Endocrinol Metab (2004) 15:375–82. doi:10.1016/j.tem.2004.08.007
43. Reznik Y, Allali-Zerah V, Chayvialle JA, Leroyer R, Leymarie P, Travert G, et al. Food-dependent Cushing’s syndrome mediated by aberrant adrenal sensitivity to gastric inhibitory polypeptide. N Engl J Med (1992) 327:981–6. doi:10.1056/NEJM199210013271403
44. Groussin L, Perlemoine K, Contesse V, Lefebvre H, Tabarin A, Thieblot P, et al. The ectopic expression of the gastric inhibitory polypeptide receptor is frequent in adrenocorticotropin-independent bilateral macronodular adrenal hyperplasia, but rare in unilateral tumors. J Clin Endocrinol Metab (2002) 87:1980–5. doi:10.1210/jcem.87.5.8458
45. Lacroix A, Hamet P, Boutin JM. Leuprolide acetate therapy in luteinizing hormone – dependent Cushing’s syndrome. N Engl J Med (1999) 341:1577–81. doi:10.1056/NEJM199911183412104
46. Goodarzi MO, Dawson DW, Li X, Lei Z, Shintaku P, Rao CV, et al. Virilization in bilateral macronodular adrenal hyperplasia controlled by luteinizing hormone. J Clin Endocrinol Metab (2003) 88:73–7. doi:10.1210/jc.2002-021292
47. Bertherat J, Contesse V, Louiset E, Barrande G, Duparc C, Groussin L, et al. In vivo and in vitro screening for illegitimate receptors in adrenocorticotropin-independent macronodular adrenal hyperplasia causing Cushing’s syndrome: identification of two cases of gonadotropin/gastric inhibitory polypeptide-dependent hypercortisolism. J Clin Endocrinol Metab (2005) 90:1302–10. doi:10.1210/jc.2004-1256
48. Lee S, Hwang R, Lee J, Rhee Y, Kim DJ, Chung U-I, et al. Ectopic expression of vasopressin V1b and V2 receptors in the adrenal glands of familial ACTH-independent macronodular adrenal hyperplasia. Clin Endocrinol (Oxf) (2005) 63:625–30. doi:10.1111/j.1365-2265.2005.02387.x
49. Mazzuco TL, Chabre O, Sturm N, Feige J-J, Thomas M. Ectopic expression of the gastric inhibitory polypeptide receptor gene is a sufficient genetic event to induce benign adrenocortical tumor in a xenotransplantation model. Endocrinology (2006) 147:782–90. doi:10.1210/en.2005-0921
50. Mazzuco TL, Chabre O, Feige J-J, Thomas M. Aberrant expression of human luteinizing hormone receptor by adrenocortical cells is sufficient to provoke both hyperplasia and Cushing’s syndrome features. J Clin Endocrinol Metab (2006) 91:196–203. doi:10.1210/jc.2005-1975
51. Herbet M, Salomon A, Feige J-J, Thomas M. Acquisition order of Ras and p53 gene alterations defines distinct adrenocortical tumor phenotypes. PLoS Genet (2012) 8:e1002700. doi:10.1371/journal.pgen.1002700
52. Groen EJ, Roos A, Muntinghe FL, Enting RH, de Vries J, Kleibeuker JH, et al. Extra-intestinal manifestations of familial adenomatous polyposis. Ann Surg Oncol (2008) 15:2439–50. doi:10.1245/s10434-008-9981-3
53. Berthon A, Martinez A, Bertherat J, Val P. Wnt/β-catenin signalling in adrenal physiology and tumour development. Mol Cell Endocrinol (2012) 351:87–95. doi:10.1016/j.mce.2011.09.009
54. Gatta-Cherifi B, Chabre O, Murat A, Niccoli P, Cardot-Bauters C, Rohmer V, et al. Adrenal involvement in MEN1. Analysis of 715 cases from the Groupe d’etude des Tumeurs Endocrines database. Eur J Endocrinol (2012) 166:269–79. doi:10.1530/EJE-11-0679
55. Shuch B, Ricketts CJ, Vocke CD, Valera VA, Chen CC, Gautam R, et al. Adrenal nodular hyperplasia in hereditary leiomyomatosis and renal cell cancer. J Urol (2013) 189:430–5. doi:10.1016/j.juro.2012.07.139
56. Rothenbuhler A, Horvath A, Libé R, Faucz FR, Fratticci A, Raffin Sanson ML, et al. Identification of novel genetic variants in phosphodiesterase 8B (PDE8B), a cAMP-specific phosphodiesterase highly expressed in the adrenal cortex, in a cohort of patients with adrenal tumours. Clin Endocrinol (Oxf) (2012) 77:195–9. doi:10.1111/j.1365-2265.2012.04366.x
57. Vezzosi D, Libe R, Baudry C, Rizk-Rabin M, Horvath A, Levy I, et al. Phosphodiesterase 11A (PDE11A) gene defects in patients with acth-independent macronodular adrenal hyperplasia (AIMAH): functional variants may contribute to genetic susceptibility of bilateral adrenal tumors. J Clin Endocrinol Metab (2012) 97:E2063–9. doi:10.1210/jc.2012-2275
58. Swords FM, Noon LA, King PJ, Clark AJL. Constitutive activation of the human ACTH receptor resulting from a synergistic interaction between two naturally occurring missense mutations in the MC2R gene. Mol Cell Endocrinol (2004) 213:149–54. doi:10.1016/j.mce.2003.10.052
59. Salpea P, Stratakis CA. Carney complex and McCune Albright syndrome: an overview of clinical manifestations and human molecular genetics. Mol Cell Endocrinol (2014) 386:85–91. doi:10.1016/j.mce.2013.08.022
60. Agarwal R, Szalkiewicz ERH, Warner RRP, Roayaie S, Hechtman JF, Zhu H, et al. Multiple endocrine neoplasia type 1 associated with a new mutation in the menin gene and a midgut neuroendocrine tumor. Pancreas (2014) 43:145–6. doi:10.1097/MPA.0b013e31829f9d3d
61. Faucz FR, Zilbermint M, Lodish MB, Szarek E, Trivellin G, Sinaii N, et al. Macronodular adrenal hyperplasia due to mutations in an armadillo repeat containing 5 (ARMC5) gene: a clinical and genetic investigation. J Clin Endocrinol Metab (2014) 99:E1113–9. doi:10.1210/jc.2013-4280
62. Gagliardi L, Schreiber AW, Hahn CN, Feng J, Cranston T, Boon H, et al. ARMC5 mutations are common in familial bilateral macronodular adrenal hyperplasia. J Clin Endocrinol Metab (2014) 99:E1784–92. doi:10.1210/jc.2014-1265
63. Stratakis CA, Kirschner LS, Carney JA. Clinical and molecular features of the Carney complex: diagnostic criteria and recommendations for patient evaluation. J Clin Endocrinol Metab (2001) 86:4041–6. doi:10.1210/jcem.86.9.7903
64. Kirschner LS, Carney JA, Pack SD, Taymans SE, Giatzakis C, Cho YS, et al. Mutations of the gene encoding the protein kinase A type I-alpha regulatory subunit in patients with the Carney complex. Nat Genet (2000) 26:89–92. doi:10.1038/79238
65. Espiard S, Ragazzon B, Bertherat J. Protein kinase A alterations in adrenocortical tumors. Horm Metab Res (2014) 46:869–75. doi:10.1055/s-0034-1385908
66. Amieux PS, Howe DG, Knickerbocker H, Lee DC, Su T, Laszlo GS, et al. Increased basal cAMP-dependent protein kinase activity inhibits the formation of mesoderm-derived structures in the developing mouse embryo. J Biol Chem (2002) 277:27294–304. doi:10.1074/jbc.M200302200
67. Lambert-Langlais S, Val P, Guyot S, Ragazzon B, Sahut-Barnola I, De Haze A, et al. A transgenic mouse line with specific Cre recombinase expression in the adrenal cortex. Mol Cell Endocrinol (2009) 300:197–204. doi:10.1016/j.mce.2008.10.045
68. de Joussineau C, Sahut-Barnola I, Levy I, Saloustros E, Val P, Stratakis CA, et al. The cAMP pathway and the control of adrenocortical development and growth. Mol Cell Endocrinol (2012) 351:28–36. doi:10.1016/j.mce.2011.10.006
69. de Joussineau C, Sahut-Barnola I, Tissier F, Dumontet T, Drelon C, Batisse-Lignier M, et al. mTOR pathway is activated by PKA in adrenocortical cells and participates in vivo to apoptosis resistance in primary pigmented nodular adrenocortical disease (PPNAD). Hum Mol Genet (2014) 23:5418–28. doi:10.1093/hmg/ddu265
70. Bourdeau I. Clinical and molecular genetic studies of bilateral adrenal hyperplasias. Endocr Res (2004) 30:575–83. doi:10.1081/ERC-200043735
71. Horvath A, Mathyakina L, Vong Q, Baxendale V, Pang ALY, Chan W-Y, et al. Serial analysis of gene expression in adrenocortical hyperplasia caused by a germline PRKAR1A mutation. J Clin Endocrinol Metab (2006) 91:584–96. doi:10.1210/jc.2005-1301
72. Cao Y, He M, Gao Z, Peng Y, Li Y, Li L, et al. Activating hotspot L205R mutation in PRKACA and adrenal Cushing’s syndrome. Science (2014) 344:913–7. doi:10.1126/science.1249480
73. Goh G, Scholl UI, Healy JM, Choi M, Prasad ML, Nelson-Williams C, et al. Recurrent activating mutation in PRKACA in cortisol-producing adrenal tumors. Nat Genet (2014) 46:613–7. doi:10.1038/ng.2956
74. Sato Y, Maekawa S, Ishii R, Sanada M, Morikawa T, Shiraishi Y, et al. Recurrent somatic mutations underlie corticotropin-independent Cushing’s syndrome. Science (2014) 344:917–20. doi:10.1126/science.1252328
75. Bertherat J, Groussin L, Sandrini F, Matyakhina L, Bei T, Stergiopoulos S, et al. Molecular and functional analysis of PRKAR1A and its locus (17q22-24) in sporadic adrenocortical tumors: 17q losses, somatic mutations, and protein kinase A expression and activity. Cancer Res (2003) 63(17):5308–19.
76. Di Dalmazi G, Kisker C, Calebiro D, Mannelli M, Canu L, Arnaldi G, et al. Novel somatic mutations in the catalytic subunit of the protein kinase A as a cause of adrenal Cushing’s syndrome: a European multicentric study. J Clin Endocrinol Metab (2014) 99:E2093–100. doi:10.1210/jc.2014-2152
77. Tissier F, Cavard C, Groussin L, Perlemoine K, Fumey G, Hagneré A-M, et al. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res (2005) 65:7622–7. doi:10.1158/0008-5472.CAN-05-0593
78. Choi M, Scholl UI, Yue P, Björklund P, Zhao B, Nelson-Williams C, et al. K+ channel mutations in adrenal aldosterone-producing adenomas and hereditary hypertension. Science (2011) 331:768–72. doi:10.1126/science.1198785
79. Zennaro M-C, Boulkroun S, Fernandes-Rosa F. An update on novel mechanisms of primary aldosteronism. J Endocrinol (2015) 224:R63–77. doi:10.1530/JOE-14-0597
80. Azizan EAB, Poulsen H, Tuluc P, Zhou J, Clausen MV, Lieb A, et al. Somatic mutations in ATP1A1 and CACNA1D underlie a common subtype of adrenal hypertension. Nat Genet (2013) 45:1055–60. doi:10.1038/ng.2716
81. Scholl UI, Stölting G, Nelson-Williams C, Vichot AA, Choi M, Loring E, et al. Recurrent gain of function mutation in calcium channel CACNA1H causes early-onset hypertension with primary aldosteronism. Elife (2015) 4:e06315. doi:10.7554/eLife.06315
82. Beuschlein F, Boulkroun S, Osswald A, Wieland T, Nielsen HN, Lichtenauer UD, et al. Somatic mutations in ATP1A1 and ATP2B3 lead to aldosterone-producing adenomas and secondary hypertension. Nat Genet (2013) 45:e1–2. doi:10.1038/ng.2550
83. Aller MI, Veale EL, Linden A-M, Sandu C, Schwaninger M, Evans LJ, et al. Modifying the subunit composition of TASK channels alters the modulation of a leak conductance in cerebellar granule neurons. J Neurosci (2005) 25:11455–67. doi:10.1523/JNEUROSCI.3153-05.2005
84. Heitzmann D, Derand R, Jungbauer S, Bandulik S, Sterner C, Schweda F, et al. Invalidation of TASK1 potassium channels disrupts adrenal gland zonation and mineralocorticoid homeostasis. EMBO J (2008) 27:179–87. doi:10.1038/sj.emboj.7601934
85. Guyon A, Tardy MP, Rovère C, Nahon J-L, Barhanin J, Lesage F. Glucose inhibition persists in hypothalamic neurons lacking tandem-pore K+ channels. J Neurosci (2009) 29:2528–33. doi:10.1523/JNEUROSCI.5764-08.2009
86. Chen AX, Nishimoto K, Nanba K, Rainey WE. Potassium channels related to primary aldosteronism: expression similarities and differences between human and rat adrenals. Mol Cell Endocrinol (2015) 417:141–8. doi:10.1016/j.mce.2015.09.011
87. Berthon A, Drelon C, Ragazzon B, Boulkroun S, Tissier F, Amar L, et al. WNT/β-catenin signalling is activated in aldosterone-producing adenomas and controls aldosterone production. Hum Mol Genet (2014) 23:889–905. doi:10.1093/hmg/ddt484
88. Åkerström T, Maharjan R, Sven Willenberg H, Cupisti K, Ip J, Moser A, et al. Activating mutations in CTNNB1 in aldosterone producing adenomas. Sci Rep (2016) 6:19546. doi:10.1038/srep19546
89. Almeida MQ, Latronico AC. The molecular pathogenesis of childhood adrenocortical tumors. Horm Metab Res (2007) 39:461–6. doi:10.1055/s-2007-981476
90. Faria AM, Almeida MQ. Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults. Mol Cell Endocrinol (2012) 351:52–7. doi:10.1016/j.mce.2011.09.040
91. Gaujoux S, Pinson S, Gimenez-Roqueplo A-P, Amar L, Ragazzon B, Launay P, et al. Inactivation of the APC gene is constant in adrenocortical tumors from patients with familial adenomatous polyposis but not frequent in sporadic adrenocortical cancers. Clin Cancer Res (2010) 16:5133–41. doi:10.1158/1078-0432.CCR-10-1497
92. Else T. Association of adrenocortical carcinoma with familial cancer susceptibility syndromes. Mol Cell Endocrinol (2012) 351:66–70. doi:10.1016/j.mce.2011.12.008
93. Giordano TJ, Kuick R, Else T, Gauger PG, Vinco M, Bauersfeld J, et al. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin Cancer Res (2009) 15:668–76. doi:10.1158/1078-0432.CCR-08-1067
94. Ribeiro TC, Latronico AC. Insulin-like growth factor system on adrenocortical tumorigenesis. Mol Cell Endocrinol (2012) 351:96–100. doi:10.1016/j.mce.2011.09.042
95. Giordano TJ, Thomas DG, Kuick R, Lizyness M, Misek DE, Smith AL, et al. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am J Pathol (2003) 162:521–31. doi:10.1016/S0002-9440(10)63846-1
96. Raymond VM, Else T, Everett JN, Long JM, Gruber SB, Hammer GD. Prevalence of germline TP53 mutations in a prospective series of unselected patients with adrenocortical carcinoma. J Clin Endocrinol Metab (2013) 98:E119–25. doi:10.1210/jc.2012-2198
97. Wasserman JD, Novokmet A, Eichler-Jonsson C, Ribeiro RC, Rodriguez-Galindo C, Zambetti GP, et al. Prevalence and functional consequence of TP53 mutations in pediatric adrenocortical carcinoma: a children’s oncology group study. J Clin Oncol (2015) 33:602–9. doi:10.1200/JCO.2013.52.6863
98. Kim AC, Reuter AL, Zubair M, Else T, Serecky K, Bingham NC, et al. Targeted disruption of beta-catenin in Sf1-expressing cells impairs development and maintenance of the adrenal cortex. Development (2008) 135:2593–602. doi:10.1242/dev.021493
99. Tadjine M, Lampron A, Ouadi L, Bourdeau I. Frequent mutations of beta-catenin gene in sporadic secreting adrenocortical adenomas. Clin Endocrinol (Oxf) (2008) 68:264–70. doi:10.1111/j.1365-2265.2007.03033.x
100. Gaujoux S, Grabar S, Fassnacht M, Ragazzon B, Launay P, Libé R, et al. β-catenin activation is associated with specific clinical and pathologic characteristics and a poor outcome in adrenocortical carcinoma. Clin Cancer Res (2011) 17:328–36. doi:10.1158/1078-0432.CCR-10-2006
101. Harada N, Tamai Y, Ishikawa T, Sauer B, Takaku K, Oshima M, et al. Intestinal polyposis in mice with a dominant stable mutation of the beta-catenin gene. EMBO J (1999) 18:5931–42. doi:10.1093/emboj/18.21.5931
102. Drelon C, Berthon A, Mathieu M, Ragazzon B, Kuick R, Batisse-Lignier M, et al. EZH2 is overexpressed in adrenocortical carcinoma and is associated with disease progression. Hum Mol Genet (2016). doi:10.1093/hmg/ddw136
103. Deb G, Thakur VS, Gupta S. Multifaceted role of EZH2 in breast and prostate tumorigenesis: epigenetics and beyond. Epigenetics (2013) 8:464–76. doi:10.4161/epi.24532
104. Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA, et al. A cancer family syndrome in twenty-four kindreds. Cancer Res (1988) 48:5358–62.
105. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science (1990) 250:1233–8. doi:10.1126/science.1978757
106. Ribeiro RC, Sandrini F, Figueiredo B, Zambetti GP, Michalkiewicz E, Lafferty AR, et al. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc Natl Acad Sci U S A (2001) 98:9330–5. doi:10.1073/pnas.161479898
107. Latronico AC, Pinto EM, Domenice S, Fragoso MC, Martin RM, Zerbini MC, et al. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J Clin Endocrinol Metab (2001) 86:4970–3. doi:10.1210/jcem.86.10.7957
108. Gicquel C, Bertagna X, Gaston V, Coste J, Louvel A, Baudin E, et al. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res (2001) 61(18):6762–7.
109. Ragazzon B, Libé R, Gaujoux S, Assié G, Fratticci A, Launay P, et al. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res (2010) 70(18):8276–81. doi:10.1158/0008-5472.CAN-10-2014
110. Lang GA, Iwakuma T, Suh Y-A, Liu G, Rao VA, Parant JM, et al. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome. Cell (2004) 119:861–72. doi:10.1016/j.cell.2004.11.006
111. Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, Bronson RT, et al. Mutant p53 gain of function in two mouse models of Li-Fraumeni syndrome. Cell (2004) 119:847–60. doi:10.1016/j.cell.2004.11.004
112. Keegan CE, Hutz JE, Else T, Adamska M, Shah SP, Kent AE, et al. Urogenital and caudal dysgenesis in adrenocortical dysplasia (acd) mice is caused by a splicing mutation in a novel telomeric regulator. Hum Mol Genet (2005) 14:113–23. doi:10.1093/hmg/ddi011
113. Colvin EK, Weir C, Ikin RJ, Hudson AL. SV40 TAg mouse models of cancer. Semin Cell Dev Biol (2014) 27:61–73. doi:10.1016/j.semcdb.2014.02.004
114. Ragazzon B, Lefrançois-Martinez A-M, Val P, Sahut-Barnola I, Tournaire C, Chambon C, et al. Adrenocorticotropin-dependent changes in SF-1/DAX-1 ratio influence steroidogenic genes expression in a novel model of glucocorticoid-producing adrenocortical cell lines derived from targeted tumorigenesis. Endocrinology (2006) 147:1805–18. doi:10.1210/en.2005-1279
115. West AN, Neale GA, Pounds S, Figueredo BC, Rodriguez Galindo C, Pianovski MAD, et al. Gene expression profiling of childhood adrenocortical tumors. Cancer Res (2007) 67:600–8. doi:10.1158/0008-5472.CAN-06-3767
116. Figueiredo BC, Cavalli LR, Pianovski MAD, Lalli E, Sandrini R, Ribeiro RC, et al. Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. J Clin Endocrinol Metab (2005) 90:615–9. doi:10.1210/jc.2004-0942
117. Pinto EM, Chen X, Easton J, Finkelstein D, Liu Z, Pounds S, et al. Genomic landscape of paediatric adrenocortical tumours. Nat Commun (2015) 6:6302. doi:10.1038/ncomms7302
118. Parker KL, Schimmer BP. Steroidogenic factor 1: a key determinant of endocrine development and function. Endocr Rev (1997) 18:361–77. doi:10.1210/edrv.18.3.0301
119. Val P, Lefrancois-Martinez A-M, Veyssiere G, Martinez A. SF-1 a key player in the development and differentiation of steroidogenic tissues. Nucl Recept (2003) 1:8. doi:10.1186/1478-1336-1-8
120. Almeida MQ, Soares IC, Ribeiro TC, Fragoso MCBV, Marins LV, Wakamatsu A, et al. Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults. J Clin Endocrinol Metab (2010) 95:1458–62. doi:10.1210/jc.2009-2040
121. Sbiera S, Schmull S, Assie G, Voelker H-U, Kraus L, Beyer M, et al. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J Clin Endocrinol Metab (2010) 95:E161–71. doi:10.1210/jc.2010-0653
122. Bielinska M, Genova E, Boime I, Parviainen H, Kiiveri S, Leppäluoto J, et al. Gonadotropin-induced adrenocortical neoplasia in NU/J nude mice. Endocrinology (2005) 146:3975–84. doi:10.1210/en.2004-1643
123. Latre de Late P, El Wakil A, Jarjat M, de Krijger RR, Heckert LL, Naquet P, et al. Vanin-1 inactivation antagonizes the development of adrenocortical neoplasia in Sf-1 transgenic mice. Endocrinology (2014) 155:2349–54. doi:10.1210/en.2014-1088
124. Juhlin CC, Stenman A, Haglund F, Clark VE, Brown TC, Baranoski J, et al. Whole-exome sequencing defines the mutational landscape of pheochromocytoma and identifies KMT2D as a recurrently mutated gene. Genes Chromosomes Cancer (2015) 54:542–54. doi:10.1002/gcc.22267
125. Hao H-X, Xie Y, Zhang Y, Charlat O, Oster E, Avello M, et al. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature (2012) 485:195–200. doi:10.1038/nature11019
126. Zheng S, Cherniack AD, Dewal N, Moffitt RA, Danilova L, Murray BA, et al. Comprehensive pan-genomic characterization of adrenocortical carcinoma. Cancer Cell (2016) 29:723–36. doi:10.1016/j.ccell.2016.04.002
127. Drelon C, Berthon A, Mathieu M, Martinez A, Val P. Adrenal cortex tissue homeostasis and zonation: a WNT perspective. Mol Cell Endocrinol (2015) 408:156–64. doi:10.1016/j.mce.2014.12.014
Keywords: adrenal, tumor, mouse models, PKA, WNT
Citation: Leccia F, Batisse-Lignier M, Sahut-Barnola I, Val P, Lefrançois-Martinez A-M and Martinez A (2016) Mouse Models Recapitulating Human Adrenocortical Tumors: What Is Lacking? Front. Endocrinol. 7:93. doi: 10.3389/fendo.2016.00093
Received: 03 May 2016; Accepted: 04 July 2016;
Published: 15 July 2016
Edited by:
Jacques Epelbaum, Institut national de la santé et de la recherche médicale, FranceReviewed by:
Maria Vrontakis, University of Manitoba, CanadaKazuhiro Takahashi, Tohoku University Graduate School of Medicine, Japan
Copyright: © 2016 Leccia, Batisse-Lignier, Sahut-Barnola, Val, Lefrançois-Martinez and Martinez. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Antoine Martinez, antoine.martinez@univ-bpclermont.fr